A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke
Stroke is a major cause of long-term disability and there are no proven medical treatments for chronic stroke. SanBio is carrying out a Phase 2 clinical trial using mesenchymal stem cells (MSCs) to help people suffering from chronic disability following a stroke. The MSCs are isolated from the bone marrow of healthy adult donors, and then modified to enhance their ability to promote recovery from injury by triggering the brain’s natural regenerative ability. Patients with stroke can suffer from loss of mobility in certain parts of their body and the hope is that this therapy will rescue some of these problems.
Double-blind randomized controlled study.
Safety and efficacy compared to sham surgery - improvement in motor activity on stroke affected side. Actively recruiting.
News about this clinical trial:
- Stem Cell Agency invests more than $44 million in treatments for stroke and fixing blood disorders in the womb
- SanBio Receives $20 Million Grant from CIRM for Stroke Clinical Trial